ketamine
Spotlight: Brain changes associated with depression treatment: a meta-analysis
Meta-analysis of data from 302 depressed subjects yielding 87 foci across 18 experiments examining various depression treatments including pharmacology, psychotherapy, electroconvulsive therapy, psilocybin, and ketamine with brain activity measures in response to emotion tasks in the scanner.
ketamine
Spotlight: NMDA receptor-modulating treatments for cognitive deficits in patients with bipolar disorder: A narrative review (Badrfam, et al, 2025)
"Ketamine infusions have improved processing speed and verbal learning in bipolar disorder patients. Evidence suggests that NMDA receptor-modulating agents play a significant role in improving cognitive function in patients with bipolar disorder. "
ketamine
Spotlight: Nonresponse to Ketamine in Treatment-Resistant Bipolar Depression (Kachlick, et al, 2025)
Ketamine demonstrates a favorable safety and tolerability profile for short time use in TRBD regardless of isolated baseline characteristics, although a more severe comorbidity burden and benzodiazepine use appear to be associated with nonresponse.
fda
Preservative-free formulation of ketamine, NRX-100, Granted FDA Fast-Track Designation for Suicidal Ideation in Patients with Depression, including Bipolar Depression
"Approximately 13 million adults seriously consider suicide each year, 1.5 million attempt suicide, and an American dies from suicide every 11 minutes. NRX-100 – IV ketamine for suicidality in patients with depression, including bipolar depression – designed to help address national crisis."
oral ketamine
Spotlight: A Preliminary Approach to Oral Low-Dose Ketamine Self-Administration in Mice (Mus musculus) (Rocha, et al, 2025)
"No significant alterations were observed in liver and kidney function in either sex, nor in inflammation, apoptosis, or DNA damage in kidney tissues. Overall, these findings support the viability of voluntary oral ketamine administration and accentuate the need to refine the proposed model"
ketamine
Spotlight: New and emerging pharmacologic treatments for MDD (Uyar, et al, 2025)
"Clinical trials have demonstrated the ability of ketamine to quickly reduce symptoms, particularly in treatment-resistant cases, with effects noticeable within hours and lasting several days post-administration."
ketamine
Spotlight: PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx™), Aligned with FDA’s CNPV National Priority Initiative
"The ketamine patch has been in development for several years and is designed to deliver controlled, sustained analgesia for both acute postoperative pain and chronic pain conditions, enabling adoption in hospital, outpatient, and home-care settings."
ketamine
Spotlight: Ketamine Reverses Chronic Stress-Induced Behavioral Changes via the Expression of Ca2+-Permeable AMPA Receptors in Mice (Flowers, et al, 2025)
"Our findings suggest that subanesthetic low-dose ketamine rapidly triggers the expression of CP-AMPARs in the hippocampus, which induces antidepressant and antistress effects."
opioid use disorder
Spotlight: Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression (Manza, et al, 2025)
Ketamine was safe and generally well-tolerated. At 10-day follow-up post-ketamine infusions, participant acceptability ratings were mostly favorable. 3-month timepoint - strong treatment adherence with self-reported depression symptoms decrease
ketamine
Spotlight: Intravenous ketamine for suicide ideation in borderline personality and depression (Bachir, et al, 2025)
"This report highlights ketamine's rapid action on glutamate pathways and its potential benefits in complex psychiatric profiles where traditional treatments like electroconvulsive therapy often fail. "
ketamine
Spotlight: A retrospective analysis of ketamine intravenous therapy for post-traumatic stress disorder in real-world care settings (McInnes, et al, 2025)
"In a large real-world sample of 8,136 PTSD patients (87 % with comorbid depression), Ketamine Intravenous Therapy (KIT) significantly reduced PTSD and depression symptoms."
ketamine
Spotlight: The association between amygdalar volume changes and depressive symptom improvements after repeated ketamine infusion in treatment-resistant depression (2025)
"The reductions in right LB volumes correlate with better clinical responses to ketamine in patients with TRD, suggesting ketamine may exert its effect by attenuating amygdalar overactivity in this population."
ketamine
Spotlight: Real world effectiveness of maintenance ketamine infusions for treatment-resistant depression in major depressive disorder and bipolar disorder (Haikazian, et al, 2025)
"Ketamine was determined to be relatively safe, with zero cases of suicidal behaviour and addiction behaviour throughout treatment."
ketamine
Spotlight "Prefrontal contribution to passive coping behaviour in chronic stress and treatment by fast-acting antidepressant" (Fong, et al, 2025)
"Persistent passive coping (p-coping) behaviour is a hallmark feature in major depression and is reversed by fast-acting antidepressants (such as ketamine)."
ketamine
Spotlight: Ketamine as an Adjunct Therapy for Refractory Cancer Pain: A Case Report (Emshoff, et al, 2025)
"While traditionally recognized for its anesthetic and dissociative effects, low-dose, subanesthetic ketamine can be useful in palliative care to manage severe, intractable pain."
uruguay
Enfoque Uruguay: Propuesta -- Estrategia Nacional de Drogas 2026-2030. Junta Nacional de Drogas
Programa Piloto de Psicoterapia Asistida con Psicodélicos en el Sistema de Salud Uruguayo | Michael DeMarco, PhD
uruguay
Propuesta para la Estrategia Nacional de Drogas 2026–2030
Programa Piloto de Psicoterapia Asistida con Psicodélicos en el Sistema de Salud Uruguayo